Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. We are the creators of three marketed products* and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization. Our core vlaues are: • Passion for innovation • Determination—being the best at what we do • Integrity—we do the right thing • We work as one team and respect each other Our core purpose is to improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products. We are also highly committed to building a sustainable and socially responsible biotech. To learn more about our technology, products, and people, please visit Disclaimer: * Out-licensed products marketed by partner



View Employees

Scott Cenci
SVP, Information Technology and Digital at Genmab
Bitten Nielsen
Senior Data Manager at Genmab
Linda Binderup Pedersen
Communications Coordinator at Genmab
Heidi Beedle
Financial Analyst at Genmab
Roberto Oliveri
Medical Director at Genmab
Eva Järlid Westerberg
VP Clinical Operations at Genmab
Patrick Engelberts
Principal Research Associate at Genmab
Carol Brunt
Manager, Administration, Finance at Genmab
Charlotte Tvermoes Rezai
Director of Quality at Genmab
Sandra Hellwig
Director, HR Business partner at Genmab

Find more contacts